Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 —— STRO-006, ITGB6-targeting ADC, enters clinic with first patient dosed; initial update expected second half of 2027 —— STRO-227, Sutro’s PTK7-target…